| Breast Cancer |
1 |
1 |
| Biologic Therapy |
0 |
0.99 |
| Targeted Cancer Therapy |
0 |
0.7 |
| Chemotherapy |
0 |
0.6 |
| HER2-Positive Breast Cancer |
0 |
0.56 |
| Toxicology |
0 |
0.54 |
| Cancer |
0 |
0.48 |
| Breast |
0 |
0.42 |
| Antineoplastic Drug |
0 |
0.4 |
| Arrhythmia |
0 |
0.26 |
| Prognosis |
0 |
0.18 |
| Indiana |
0 |
0.12 |
| Care and Maintenance of Vision |
0 |
0.09 |
| Cataract |
0 |
0.08 |
| A-Scan Biometry |
0 |
0.06 |
| Aromatase Inhibitors |
0 |
0.06 |
| Clinical Research |
0 |
0.06 |
| Endocrine Therapy |
0 |
0.06 |
| Hormonal Therapy |
0 |
0.06 |
| Humanized Monoclonal Antibody |
0 |
0.06 |
| Luteinizing Hormone-Releasing Hormone (LHRH) Agonists |
0 |
0.06 |
| Memory |
0 |
0.06 |
| Myelosuppression |
0 |
0.06 |
| Neoadjuvant Therapy |
0 |
0.06 |
| Quality of Life |
0 |
0.06 |
| Residual Disease |
0 |
0.06 |
| Scan |
0 |
0.06 |
| Spain |
0 |
0.06 |
| Surgery |
0 |
0.06 |